no DNCR (n = 235) | DNCR (n = 64) | |
---|---|---|
Surgical technique | ||
RARP | 107 (45.5) | 30 (46.9) |
ORP | 128 (54.5) | 34 (53.1) |
Duration of surgery, min | 185 (160–210) | 193 (163–218) |
Estimated blood loss, ml | 600 (300–900) | 500 (250–900) |
Midazolam for premedication | 212 (91.4) | 61 (95.3) |
Anesthetic technique | ||
Balanced anesthesia | 130 (55.3) | 31 (48.4) |
TIVA | 105 (44.7) | 33 (51.6) |
Additional spinal anesthesia | 60 (20.1) | 14 (4.7) |
Sufentanil, µga | 90 (70–100) | 90 (65–100) |
High vasopressor supportb | 196 (83.4) | 52 (81.3) |
Duration of anesthesia, min | 265 (235–290) | 270 (237.5–302.5) |
Fluids, mlc | 2500 (2000–3000) | 2500 (2000–3000) |
PSA preoperative, ng/ml | 7.2 (5.2–11.2) | 7.7 (4.8–12.8) |
Neoadjuvant androgen deprivation therapy | 11 (4.7) | 7 (10.9) |
Prostate volume (sonographic assessment), ml | 36 (28–50) | 44 (29–56) |
Prostate volume (histopathologic assessment), ml | 25 (20–35) | 30.1 (20–45) |
Tumor volume, ml | 4.6 (2.4–8.4) | 5.4 (3.1–12.2) |
Resected lymph nodes | 14 (8–22) | 13 (7–21) |
N stage | ||
N0 | 187 (79.6) | 42 (65.6) |
N1 | 31 (13.2) | 16 (25.0) |
Nx | 17 (7.2) | 6 (9.4) |
T stage | ||
pT2a-2c | 155 (66.0) | 32 (50.0) |
pT3a-3c | 80 (34.0) | 32 (50.0) |
Gleason scored | ||
1 | 15 (6.4) | 4 (6.3) |
2 | 144 (61.3) | 33 (51.6) |
3 | 52 (22.1) | 15 (23.4) |
4 | 2 (0.9) | 0 (0.0) |
5 | 22 (9.4) | 12 (18.8) |
Positive surgical margin | ||
R0 | 187 (79.6) | 43 (67.2) |
R1 | 48 (20.4) | 20 (31.3) |
Rx | 0 (0.0) | 1 (1.6) |